Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Breaking News

Medical Marijuana Inhaler Coming to Israel

— Teva Pharmaceutical Industries of Israel will market and distribute a cannabis inhaler in the country, becoming the first major medical company in the world to do so.

Teva signed an agreement to exclusively market and distribute the inhaler developed and manufactured by the Tel Aviv-based company Syqe Medical, the companies said in a statement Monday.

Syqe said it was the first time that a major global pharmaceutical company would market a medical cannabis product, according to The Times of Israel. The inhaler has been used at the Rambam Hospital in Haifa.

Israel’s Health Ministry was expected to approve the device for use by patients at home by 2017.

“Teva Israel is entering the field of medical cannabis out of a deep commitment to patients coping with pain, which is one of the company’s core therapeutic areas,” said its CEO, Avinoam Sapir, according to The Times of Israel.

A message from our editor-in-chief Jodi Rudoren

We're building on 127 years of independent journalism to help you develop deeper connections to what it means to be Jewish today.

With so much at stake for the Jewish people right now — war, rising antisemitism, a high-stakes U.S. presidential election — American Jews depend on the Forward's perspective, integrity and courage.

—  Jodi Rudoren, Editor-in-Chief 

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.